Soleno Therapeutics (SLNO) Reports Strong Q3 Earnings Despite VYKAT XR Safety Concerns

Despite the beardown results, the company’s stocks tumbled that day. Investor concerns regarding discontinuation rates for VYKAT XR, the company’s attraction for hyperphagia (extreme hunger) successful patients with Prader-Willi syndrome (PWS) look to beryllium the main origin of the company’s crisp banal decline.

In a akin vein, Piper Sandler had reaffirmed an Overweight standing and $145 terms people for Soleno Therapeutics, Inc. (NASDAQ:SLNO) backmost successful aboriginal October, implying that the banal had been oversold owed to caller information issues. According to the firm, concerns implicit the information of the company’s VYKAT XR medication, which were raised successful the FDA Adverse Event Reporting System database, and a little thesis published successful August are what person led to the company’s banal declines.

However, Piper Sandler maintained its optimism regarding VYKAT XR’s ongoing motorboat and saw the banal driblet arsenic a “compelling buying opportunity” for investors.

Soleno Therapeutics, Inc. (NASDAQ:SLNO) is simply a clinical-stage biopharmaceutical institution that develops and commercializes caller therapeutics to dainty uncommon diseases.

While we admit the imaginable of SLNO arsenic an investment, we judge definite AI stocks connection greater upside imaginable and transportation little downside risk. If you're looking for an highly undervalued AI banal that besides stands to payment importantly from Trump-era tariffs and the onshoring trend, spot our escaped study connected the best short-term AI stock.

READ NEXT: 10 Best Magic Formula Stocks for 2025 and 10 Best Retirement Stocks to Buy According to Hedge Funds.

Disclosure: None. This nonfiction is primitively published at Insider Monkey.